Cite
Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.
MLA
Simon, Matthew S., et al. “Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia Microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.” Clinical Infectious Diseases, vol. 65, no. 7, Oct. 2017, pp. 1222–25. EBSCOhost, https://doi.org/10.1093/cid/cix477.
APA
Simon, M. S., Westblade, L. F., Dziedziech, A., Visone, J. E., Furman, R. R., Jenkins, S. G., Schuetz, A. N., & Kirkman, L. A. (2017). Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Clinical Infectious Diseases, 65(7), 1222–1225. https://doi.org/10.1093/cid/cix477
Chicago
Simon, Matthew S., Lars F. Westblade, Alexis Dziedziech, Joseph E. Visone, Richard R. Furman, Stephen G. Jenkins, Audrey N. Schuetz, and Laura A. Kirkman. 2017. “Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia Microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia.” Clinical Infectious Diseases 65 (7): 1222–25. doi:10.1093/cid/cix477.